The partnership combines Sun Pharma’s expertise in product development using Sun Pharma Advanced Research Company’s (SPARC) proprietary platform technologies and manufacturing network with Merck’s clinical development and registration expertise and a broad, geographic commercial footprint.
The joint venture will be structured through Merck and Sun Pharma‘s respective subsidiaries.
The collaboration between Sun Pharma and MSD Pharmaceuticals, the Indian arm of the US drugmaker, will be managed by a joint board and leadership team, consisting of members of senior management from both companies.
Merck/MSD Emerging Markets president Kevin Ali said by combining forces with Sun Pharma they are complementing the innovative product portfolio with a solid foundation for addressing the diverse needs of patients, physicians and governments across the Emerging Markets.